Evidence map›Paper›PMID 39153088›Full record

ArticleNeuroradiology2024

Distinguishing glioblastoma progression from treatment-related changes using DTI directionality growth analysis.

R van den Elshout, B Ariëns, M Esmaeili, B Akkurt, M Mannil, F J A Meijer, A G van der Kolk, T W J Scheenen, D Henssen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuroradiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

R van den ElshoutDepartment of Medical Imaging, Radboud University Medical Center, Geert Grooteplein Zuid 10, Nijmegen, 6525 GA, the Netherlands. rik.vandenelshout@outlook.com.ORCID http://orcid.org/0000-0002-8765-3017
B AriënsAmsterdamUMC, Radiology and Nuclear Medicine, Amsterdam, Netherlands.
M EsmaeiliDepartment of Diagnostic Imaging, Akershus University Hospital, Lørenskog, Norway.
B AkkurtUniversity Clinic for Radiology, Westfälische Wilhelms-University Muenster and University Hospital Muenster, Muenster, Germany.
M MannilUniversity Clinic for Radiology, Westfälische Wilhelms-University Muenster and University Hospital Muenster, Muenster, Germany.
F J A MeijerDepartment of Medical Imaging, Radboud University Medical Center, Geert Grooteplein Zuid 10, Nijmegen, 6525 GA, the Netherlands.
A G van der KolkDepartment of Medical Imaging, Radboud University Medical Center, Geert Grooteplein Zuid 10, Nijmegen, 6525 GA, the Netherlands.
T W J ScheenenDepartment of Medical Imaging, Radboud University Medical Center, Geert Grooteplein Zuid 10, Nijmegen, 6525 GA, the Netherlands.
D HenssenDepartment of Medical Imaging, Radboud University Medical Center, Geert Grooteplein Zuid 10, Nijmegen, 6525 GA, the Netherlands.

Funding

Helse Sør-Øst RHF 2018047ZonMw 04510012110042
6 · The paper itself

Abstract

backgroundIt is difficult to distinguish between tumor progression (TP) and treatment-related abnormalities (TRA) in treated glioblastoma patients via conventional MRI, but this distinction is crucial for treatment decision making. Glioblastoma is known to exhibit an invasive growth pattern along white matter architecture and vasculature. This study quantified lesion development patterns in treated glioblastoma lesions and their relation to white matter microstructure to distinguish TP from TRA. MATERIALS AND

methodsGlioblastoma patients with confirmed TP or TRA with T1-weighted contrast-enhanced and DTI MR scans from two posttreatment follow-up timepoints were reviewed. The contrast-enhancing regions were segmented, and the regions were coregistered to the DTI data. Lesion increase vectors were categorized into two groups: parallel (0-20 degrees) and perpendicular (70-90 degrees) to white matter. FA-values were also extracted. To test for a statistically significant difference between the TP and TRA groups, a Mann‒Whitney U test was performed.

resultsOf 73 glioblastoma patients, fifteen were diagnosed with TRA, whereas 58 patients suffered TP. TP had a 25.8% (95% CI 24.1%-27.6%) increase in parallel lesions, and TRA had a 25.4% (95% CI 20.9%-29.9%) increase in parallel lesions. The perpendicular increase was 14.7% for TP (95% CI 13.0%-16.4%) and 18.0% (95% CI 13.5%-22.5%) for TRA. These results were not significantly different (p = 0.978). FA value for TP showed to be 0.248 (SD = 0.054) and for TRA it was 0.231 (SD = 0.075), showing no statistically significant difference (p = 0.121).

conclusionsBased on our results, quantifying posttreatment contrast-enhancing lesion development directionality with DTI in glioblastoma patients does not appear to effectively distinguish between TP and TRA.

Indexed as

Brain NeoplasmsContrast MediaDiffusion Tensor ImagingDisease ProgressionGlioblastomaAdultAgedDiagnosis, DifferentialFemaleHumansImage Interpretation, Computer-AssistedMaleMiddle AgedRetrospective StudiesContrast MediaDTIGlioblastomaLesion developmentMRISatellitosis

Identifiers

PMID39153088
PMCPMC11611950

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.